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Abstract
Background: The knee is symptomatically the most frequent affected joint in osteoarthritis and, in the Netherlands
and other Western countries, is mainly managed by general practitioners (GPs). An intra-articular glucocorticoid
injection is recommended in (inter) national guidelines for patients with knee osteoarthritis as an option for a flare
of knee pain and/or for those who are not responding well to pain medication. An innovative approach that could
replace the intra-articular injection is an intramuscular gluteal glucocorticoid injection. An intramuscular injection is
easier to perform than an intra-articular injection with lesser risk of severe local adverse reactions. We hypothesize
that intramuscular gluteal glucocorticoid injection is non-inferior in reducing knee pain compared to intra-articular
glucocorticoid injection, with potentially a longer lasting effect than intra-articular injection.
Methods/design: The study will be a pragmatic randomized controlled non-inferiority trial with two parallel groups. A
total of 140 patients aged 45 years and older with knee osteoarthritis who contacted their general practitioner and
have persistent knee pain (score≥ 3 on 0–10 numerical rating scale; 0 = no knee pain) will be included.
Patients will be randomly allocated (1:1) to an injection of 40mg triamcinolone acetonide intra-articular in the knee
joint or intramuscular in the ipsilateral ventrogluteal area.
The effect of treatment will be evaluated by questionnaires at 2, 4, 8, 12, and 24weeks after injection. The primary outcome
is patients’ reported severity of knee pain measured with the pain subscale of the Knee injury and Osteoarthritis Outcome
Score 4weeks after injection. Statistical analysis will be based on both the per-protocol and the intention-to-treat principle.
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Discussion: This study will evaluate non-inferiority of intramuscular glucocorticoid injection compared to intra-articular
glucocorticoid injection for knee osteoarthritis symptoms.
Trial registration: This trial is registered in the Dutch Trial Registry (number NTR6968) at 2018-01-22 (https://www.
trialregister.nl/trial/6784). Issue date: 1 October 2019.
Trial sponsor: Erasmus MC University Medical Center Rotterdam.
PO-box 2040.
3000 CA Rotterdam.
The Netherlands.
Keywords: Knee osteoarthritis, Glucocorticoid injection, Intra-articular, Intramuscular, Randomized controlled trial, Non-
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Background
The knee is symptomatically the most frequent affected
joint in osteoarthritis (OA). In the Netherlands and
other Western countries this is mainly managed by gen-
eral practitioners [1]. The prevalence of knee OA in gen-
eral practice was estimated around 40.2 per 1000 patient
years (28.9 men; 51.4 women) in 2018 [2].
For OA patients, pain and disability are the most im-
portant reasons to seek care of a health professional [3–
5]. If patients are not responding satisfactorily to para-
cetamol, NSAIDs and non-drug treatment, or in cases of
interim aggravation, the evidence-based guideline from
the Dutch College of General Practitioners on ‘Non-
traumatic knee complaints’ suggests intra-articular (IA)
glucocorticoid injection with 20 to 40 mg triamcinolone
acetonide [6]. In several international guidelines IA
glucocorticoid injection is also recommended for these
abovementioned indications [7, 8].
Despite the long-standing frequent application of IA
glucocorticoids, there is an ongoing debate about their
effectiveness and safety [9, 10]. IA glucocorticoid injec-
tion in patients with knee OA leads to a moderate im-
provement in pain, but only in the short term (1 to 6
weeks after injection) [9]. IA injection has a small risk of
the serious adverse reaction of septic arthritis on the
short term [11]. In recent literature there is controversy
over the chondrotoxicity of IA glucocorticoids on the
longer term [12–14].
An additional obstacle in the way of IA injection is that
GPs might feel incompetent to administer this type of injec-
tion due to lack of training and experience [15]. Due to the
GP’s restraint, knee OA patients who could benefit from IA
injection might not always receive timely injection [15].
Intramuscular (IM) glucocorticoid injection could be a
valuable alternative treatment for IA glucocorticoid in-
jection for patients with knee OA. IM administration
eliminates the risk of septic arthritis and direct cartilage
toxicity. The favorable effect of IM glucocorticoids on
musculoskeletal pain has been studied originally in pa-
tients with rotator cuff disease and is used for
rheumatoid arthritis [16, 17]. In a recent study from our
study group, a clinical relevant and statistical significant
difference in pain reduction was found for IM gluco-
corticoid injection compared to placebo in patients with
hip OA [18]. Remarkably, the clinically relevant effect of
the IM injection lasted at least 12 weeks. As of now no
direct comparison between the effectiveness of IM and
IA glucocorticoid injection in knee OA has been made.
We will perform a randomized controlled two-
parallel-groups trial in patients with knee OA included
from general practices, assessing the non-inferiority of
an IM gluteal glucocorticoid injection compared to an
IA glucocorticoid knee injection at 4 weeks follow-up.
We hypothesize that IM gluteal glucocorticoid injection
is non-inferior to IA glucocorticoid injection in reducing
knee pain 4 weeks after injection, with potentially a lon-
ger lasting effect for at least 12 weeks.
Primary objective
The primary objective is to assess whether IM gluteal
glucocorticoid injection is non-inferior to IA knee gluco-
corticoid injection in reducing knee pain, measured with
the Knee injury and Osteoarthritis Outcome Score
(KOOS) pain subscale, in patients with knee OA in gen-
eral practice at 4 weeks after injection.
Secondary objectives
The study will evaluate the differences in reported adverse
events frequency and co-interventions of patients allo-
cated to an IM gluteal glucocorticoid injection or to an IA
glucocorticoid injection. Differences between the two
treatment groups in several outcome measures related to
knee recovery, on short and longtime follow-up (2–24
weeks) and quality of life will be measured (see Table 2).
Methods
Design
This study is a pragmatic randomized controlled non-
inferiority trial with two parallel groups with a follow-up
of 24 weeks (see Fig. 1). The Medical Ethics Committee
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of Erasmus MC University Medical Center Rotterdam
approved this trial (MEC 2017–563). Any modifications
to the protocol which may impact on the conduct of the
study, potential benefit of the patient or may affect pa-
tient safety, including changes of study objectives, study
design, patient population, sample sizes, study proce-
dures, or significant administrative aspects will require a
formal amendment to the protocol. Such amendment
will be approved by the Medical Ethics Committee of
Erasmus MC University Medical Center Rotterdam prior
to implementation. All patients will give written in-
formed consent prior to data collection.
Patient selection
Patients with OA of the knee will be recruited by partici-
pating GPs located in the South-West of the Netherlands.
Patient selection can take place in two different ways. The
electronic patient files will be scanned for the Inter-
national Classification of Primary Care (ICPC) codes L90
(knee OA) and L15 (knee symptoms/complaints) in order
to identify eligible patients who have no contraindications
for participation in this study. See Table 1 for the inclu-
sion- and exclusion criteria. Patients who are identified
with the ICPC code L15 are only selected if there is a note
by the GP or a radiology report that mentions ‘osteoarth-
ritis’ or ‘cartilage degeneration’.
The second way is that GPs are asked to invite patients
who consult them for knee OA to participate in the
study. The GPs are asked to screen the inclusion- and
exclusion criteria for all patients and will also directly as-
sess whether there is an indication for glucocorticoid in-
jection. An intra-articular glucocorticoid injection is
recommended in guidelines for patients with knee osteo-
arthritis as an option for a flare of knee pain and/or for
those who are not responding well to pain medication.
Patients who have had an IA injection in the knee dur-
ing the previous 6 months will be excluded, since a pro-
longed treatment effect of 24 weeks after injection has
been described [19]. Patients with diabetes mellitus on
insulin therapy or with a poor glycemic control (as
Fig. 1 Flow-chart of patient selection
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assessed by their GP) cannot participate, as they
might be at risk of prolonged blood glucose level ele-
vation after glucocorticoid injection [20, 21]. Patients
who have been referred to an orthopedic surgeon will
also be excluded from participation considering that
these patients could become candidates for total knee
or hip arthroplasty during the follow-up period of the
study. The risk of periprosthetic joint infection (PJI)
is increased in patients who received an IA gluco-
corticoid injection in the 3 months prior to arthro-
plasty [22, 23]. It is not known if IM glucocorticoid
injection increases the risk of PJI.
For patients who are selected via their electronic pa-
tient file, the actual amount of knee pain they experience
is not known by their GP. These patients’ knee pain level
will be checked over the phone by the researchers (given
that the patient is willing to participate in the study, see
Fig. 1). A minimum score of 3 on the numerical rating
scale (NRS, 0–10; 0 = no knee pain) is required in order
to participate in the trial. If a patient has an NRS knee
pain score < 3, the patient will be asked to contact the
research team in case of future increase in knee pain. In
case a patient has bilateral knee OA, the most painful
knee is selected as the ‘study knee’.
Procedures
The GPs will inform all eligible patients about the study
in writing. Patients will receive information about the
study and a reply card. Once the research team receives
a reply card with a positive response from a patient, a re-
searcher will contact this patient by telephone. The re-
searcher will ask the patient about the severity of knee
pain averaged over the past week. To all patients with a
pain score ≥ 3 additional written information about the
study will be sent. Some days later, the researcher or
trained research assistant will contact the patients again
to further explain the study and to answer remaining
questions. Patients who are interested to participate will
be asked to give written informed consent. After the pa-
tients have given this consent, the baseline questionnaire
is sent to these patients.
After completion of the baseline questionnaire, the pa-
tient will be randomly allocated to one of the two treat-
ment groups. The GP and the patient will be informed
about the outcome of randomization. The GP will pre-
pare and administer the allocated injection. We aim to
have the injection administered within 1 week after com-
pletion of the baseline questionnaire. This is to ascertain
the pain score at the moment of injection is unchanged
or close to the baseline score. Change in pain since base-
line can never lead to exclusion of a trial participant.
The GP will complete a case report form at the pa-
tients’ visit for administration of the injection. This re-
port form asks for the American College of
Rheumatology criteria for clinical diagnosis of knee OA,
location of injection, severity of knee pain averaged over
the past week and the batch number of the triamcino-
lone acetonide [24].
All patients will be referred for an AP weight-
bearing X-ray of the studied knee if an X-ray has not
been made in the 12 months prior to enrolment. The
12 month period was chosen as the risk of annual
radiographic OA progression by at least one Kellgren-
Lawrence (K-L) grade has been estimated low [25].
Therefore, the X-ray does not have to be obtained
directly at baseline, but will be made during follow-
up. We consider the radiograph necessary in order to
facilitate comparison between our study population
and patient data collected in previous studies. Two
researchers will independently assess the X-rays to
grade radiographic knee OA, using the K-L classifica-
tion [26].
Randomization
After the patients sign informed consent, they will be
randomized and receive their allocated intervention.
After informed consent the patient will be assigned a
unique trial number.
An independent researcher, who will not meet or
contact the patients, has prepared a computer
generated randomization list using 1:1 allocation and
random blocks of 8, 6 or 4 in order to ensure con-
cealment of allocation.
Table 1 Eligibility criteria
Inclusion criteria:
1) contacted their GPa (consultation and/or repeat pain medication
prescription) due to knee OAb (ICPCc L90 or L15) during the past 5
years;
2) aged 45 years and over;
3) symptomatic knee OA for at least 3 months prior to enrolment;
4) a minimum score of 3 on the NRSd asking about the severity of knee
pain averaged over the past week (0–10; 0 = no knee pain);
5) glucocorticoid injection is indicated in this patient
Exclusion criteria:
1) use of oral glucocorticoids;
2) intra-articular injection in a knee in the previous 6 months;
3) allergy to glucocorticoids;
4) local or systemic infection, recent vaccination with live attenuated
vaccine;
5) type 1 diabetes mellitus, type 2 diabetes mellitus on insulin therapy,
poorly controlled type 2 diabetes mellitus;
6) presence of inflammatory rheumatic diseases (such as rheumatoid
arthritis, psoriatic arthritis, spondylartropathies);
7) coagulopathy, use of anticoagulants, use of dual antiplatelet therapy;
8) a history of gastric/duodenal ulcer or a present gastric/duodenal
ulcer;
9) currently receiving care of an orthopaedic surgeon for OA of the hip
and/or knee;
10) incapacity to complete questionnaires in Dutch;
11) incapacity to give informed consent.
aGP General Practitioner bOA Osteoarthritis cICPC International Classification of
Primary Care dNumeric Rating Scale
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Blinding
Due to the pragmatic nature of this trial, the patient and
the GP are not blinded for treatment allocation. The re-
searcher involved in data analysis will be blinded for treat-
ment allocation.
Intervention
The investigational treatment will consist of 40 mg
triamcinolone acetonide (Kenacort-A 40). The chosen
dosage of glucocorticoid is based on clinical experi-
ence [27]. No local anesthetic will be added to the in-
jection. The GP will inject either IA in the knee joint
or IM in the ipsilateral ventrogluteal region. All par-
ticipating GPs will be invited for an optional IA knee
injection training under supervision of an experienced
orthopedic surgeon (PKB).
The superolateral IA injection approach to the knee
will be used (just below the upper border of the
patella and 1 cm lateral to the lateral border of the
patella, see Fig. 2b). This approach has an accuracy of 91%
for needle placement in the IA space of the knee and is
recommended by the Dutch College of GPs [6, 28].
The IM injection will be administered in the ven-
trogluteal region (the region between the iliac crest,
greater trochanter of the femur and anterior iliac
spine, see Fig. 2a) in order to prevent injury to the
sciatic nerve [29, 30]. Moreover, administration in the
ventrogluteal region diminishes the possibility of sub-
cutaneous injection in overweight patients since the
layer of subcutaneous fat is less thick in the ventro-
gluteal region compared to the dorsogluteal region
[31]. It is well known that knee OA is more common
in patients with a BMI > 27 kg/m2 [32].
Co-interventions are allowed during the follow-up and
will be monitored.
Measurements
Baseline measurements
See Table 2 for an overview of baseline measurements.
Demographic measurements consist of age, sex, educa-
tional level, and daily occupation. Also self-reported
length and weight are reported. Medication use for knee
OA will be measured using a multiple choice format
where patients can select multiple answers and add a
missing medicament.
Intermittent and constant OA pain will be measured
with the Intermittent and Constant OsteoArthritis Pain
score (ICOAP:0–100; 0 = no pain) [33]. Knee complaint
characteristics (duration of symptoms at baseline, sensa-
tion of swelling in the knee as an indicator of flare-up)
will be recorded. Knee pain severity averaged over the
last week will be measured with an 11-point numerical
rating scale (NRS:0–10; 0 = no pain). Health related
Quality of Life (QoL) will be measured with the EQ-5D-
5 L (scores ranging from − 0.446 = worst health related
QoL to 1.0 = perfect health related QoL) [34, 35] Co-
morbidity will be measured at baseline using a multiple
choice format where patients can select multiple answers
and add a missing comorbid disease. Also measured at
baseline will be physical activity over the past week
(IPAQ short), neuropathic pain (modified painDETECT
questionnaire), patients’ preferred injection site (knee or
ventrogluteal area) and patients’ expected treatment re-
sponse [36, 37].
Follow-up measurements
Outcomes are measured at 2, 4, 8, 12 and 24 weeks after
administration of the injection using digital question-
naires. Patients without an electronic mailbox will re-
ceive paper questionnaires. The primary outcome is
patient reported severity of pain at 4 weeks after injec-
tion measured with the KOOS pain subscale (0–100; 0 =
Fig. 2 Ventrogluteal intramuscular and superolateral intra-articular injection techniques
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extreme pain). Secondary study endpoints are listed in
Table 2. Patients’ perceived recovery is measured with
a 7-point Likert scale that will be dichotomized in re-
covered (‘complete recovery’, ‘much improved’,
‘slightly improved’) and not-recovered (‘no change’,
‘slightly worse’, ‘much worse’,“worse than ever’) [18].
Percentage responders is defined by the OMERACT-
OARSI criteria: High improvement (≥50%) in KOOS
pain subscale or in KOOS function in daily living
subscale and absolute increase ≥20 points in KOOS
pain subscale or function in daily living subscale, if
not then improvement in at least 2 of the 3 following
domains: 1) ≥20% improvement in KOOS pain sub-
scale and ≥ 10 points increase in KOOS pain subscale,
2) ≥20% improvement in KOOS function in daily liv-
ing subscale and ≥ 10 points increase in KOOS func-
tion in daily living subscale, 3) ≥20% increase in
global score and ≥ 10 points increase in global score.
In this study patients’ global score will be measured
with a patients’ perceived recovery score measured on
a 7-point Likert scale. This domain is considered im-
proved if a patient fills in ‘complete recovery’, ‘much
improved’, or ‘slightly improved’ [38]. Two weeks
after administration of the injection patients are asked
to report adverse events. Also, follow-up question-
naires at all time points ask about hospitalization to
monitor Serious Adverse Events. Co-interventions in-
cluding medication, non-drug therapies such as
physiotherapy, referrals and surgery will be measured
with the modified medical consumption questionnaire
of the Institute for Medical Technology Assessment
(iMCQ) [39]. Experienced painfulness of injection will
be registered 2 weeks after glucocorticoid injection.
All data will be handled according to the Data Moni-
toring Plan, as drafted and approved by the funder in
preparation of data collection.
Table 2 Scheduled measurements of primary and secondary outcomes
Measurement Baseline Injection 2 weeks fu 4 weeks fu 8 weeks fu 12 weeks fu 24 weeks fu
Primary outcome measure
KOOS pain subscale x x x x x x
Secondary outcome measures
Adverse events x
Hospitalization x x x x x
Co-interventions (iMCQ) x x x x x
Medication use for knee OA x x x x x x
Re-injection with glucocorticoid x x x
KOOS stiffness x x x x x x
KOOS function in daily living x x x x x x
KOOS sports and recreation x x x x x x
KOOS QoL x x x x x x
ICOAP x x x x x x
OMERACT OARSI responder criteria x x x x x
Knee pain over past week (NRS) x x x x x x x
Perceived recovery (Likert scale) x x x x x
Knee complaint characteristics x x x x x x
Health related QoL x
Additional measurements
Radiograph of study knee x
Check of ACR criteria x
Painfulness of injection (NRS) x
Demographic information x
Co-morbidity x
Physical activity over the past week (IPAQ short) x
Neuropathic pain (Modified painDETECT Questionnaire) x
Patients’ preferred injection site x
Patients’ expected treatment response x
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Sample size
For the sample size calculation, we used data from the
study of Henriksen et al. that evaluated the clinical bene-
fits of an IA glucocorticoid injection given before exer-
cise therapy in patients with knee OA [40]. The results
of the study reported a baseline standard deviation of 16
for the KOOS pain (recommended by the KOOS for
sample size calculations is a standard deviation of 15).
The minimal important difference (=non-inferiority
margin) between both treatment groups of the patient
reported outcome KOOS (0–100) was set at 7 points (ef-
fect size of 0.44) [41, 42].
For the non-inferiority of an IM gluteal glucocorticoid
injection compared to an IA knee glucocorticoid injec-
tion, we will need 65 patients per group, using a power
of 80%, an alpha of 5%, a non-inferior margin of 7 and a
SD of 16. Taking into account a loss to follow-up of 5%,
this trial needs to include (2*65) + (0.05*2*65) = ~ 140
patients. We expect a low percentage of loss to follow-
up because of the relative short follow-up period of 24
weeks and our prior experience in glucocorticoid trials
[18, 43].
Data analyses
Imbalance in the baseline variables of the two treatment
arms might occur after randomization. This is problem-
atic if the imbalanced variable is related to the outcome
variable, as this could lead to confounding [44, 45]. In
case imbalance occurs, we will adjust for relevant vari-
ables. Descriptive statistics will be used to describe pa-
tients’ and complaints characteristics at baseline.
Analyses will be adjusted for variables that hamper the
baseline interchangeability of groups when there are
clinically relevant differences between groups of over
10%.
The primary outcome is patient reported severity of
pain at 4 weeks after injection measured with the KOOS
pain (0–100; 0 = extreme pain). We will use a non-
inferiority design to assess if an IM gluteal injection is
non-inferior to an IA knee injection with regard to this
outcome. In non-inferiority comparisons intention-to-
treat analysis can bias towards the null and could
increase type I error; the risk of falsely claiming non-
inferiority [46]. Therefore, the per-protocol analysis will
be the primary analysis. Included in the per-protocol
analysis will be patients who received the assigned injec-
tion and reported the KOOS pain at 4 weeks follow-up.
In case a patient from the IM injection group receives
an additional IA injection earlier than 6 weeks after the
study injection, this will be considered as a protocol
violation and the patient will be excluded from the per-
protocol analysis. The reason for this is that the guide-
line from the Dutch College of General Practitioners
recommends to leave at least 6 weeks between two
consecutive injections [6]. Non-inferiority of the IM in-
jection will also be assessed using both intention-to-treat
and per-protocol analysis at 2, 8, 12 and 24 weeks
follow-up and for the outcome KOOS pain. For the
other outcome measures we will calculate mean
differences.
We expect 10–15% of missing data (incompletely filled
in paper questionnaires and loss to follow-up). We will
contact the patients to pose them the missing questions
again in order to minimize missing data for the primary
outcome. Multiple imputations will be performed for
missing values (incompletely filled in questionnaires),
creating at least five imputed datasets.
Linear mixed models with repeated measures will be
used to calculate group differences over time for the pri-
mary outcome as this is a continuous variable. To model
the covariance of repeated measures by patients, a struc-
ture will be chosen with the lowest Akaike’s information
criterion. Fixed effects will be time, and time by
treatment.
Linear mixed models with repeated measures will also
be used for the continuous secondary outcomes: KOOS,
NRS, WOMAC, ICOAP, and EQ-5D-5 L. Generalized
estimating equations analyses with repeated measures
will be performed for the dichotomous outcomes: pa-
tients’ perceived recovery (7 point Likert scale), and the
OMERACT-OARSI responder criteria. Before general-
ized estimating equations analyses, multiple imputations
will be performed for missing values of secondary study
parameters, creating at least five imputed datasets.
When patients underwent a total knee replacement
surgery, data of these patients will be included up to the
date of surgery. Missing data for secondary outcome
measurements will be handled similarly as missing data
for the primary outcome.
Subgroup analysis
An explorative, pre-defined, subgroup analysis will be
performed assessing the interaction effects between in-
jections regarding the severity of knee pain at baseline
(NRS pain score of > = 7 versus < 7) on the primary out-
come [47]. Generalized estimating equations will be used
to analyze differences between groups concerning ad-
verse events, medical consumption and medication
usage.
Discussion
This study will evaluate non-inferiority of intramuscular
glucocorticoid injection compared to intra-articular
glucocorticoid injection for knee osteoarthritis symp-
toms, during 24 weeks of follow-up. The primary out-
come is the patient reported severity of pain at 4 weeks
after injection, using a non-inferiority margin of 7 points
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on the patient reported outcome KOOS between both
treatment groups.
The sample size calculations indicated a required sam-
ple of 140 participants, taking into account a loss to
follow-up of 5%. Recruitment was finalized on February
11, 2020.
Strength and limitations
The current study is a high-quality pragmatic trial,
which will provide a reliable comparison between intra-
articular and intramuscular corticosteroid injections for
individuals with knee OA and will make implementation
of its results highly feasible. Obviously, patients will not
be blinded to the location of the injection in the current
study. Although this might bias the results towards the
by the patients preferred injection location (patients’
preference will be assessed), we already know from our
previous study on hip OA [18] that the intramuscular
corticosteroid injection was superior to placebo. So the
clinical effectiveness of the intramuscular corticosteroid
injection did not rely on contextual effects only.
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